Subcutaneous golimumab is safe and effective in rheumatoid arthritis patients with low disease activity who previously received TNF inhibitors

Primary tabs

NEWS
Subcutaneous golimumab is safe and effective in rheumatoid arthritis patients with low disease activity who previously received TNF inhibitors

Rheumatoid arthritis (RA) is an autoimmune disease that causes inflammation in the joints thereby resulting in swelling, immobility and pain in the joint area. Golimumab is a tumor necrosis factor (TNF) inhibitor that blocks a protein (TNF-alpha) which causes inflammation, thereby improving the RA symptoms.

Wakabayashi H et al evaluated the efficacy and safety of subcutaneous golimumab (GLM-SC) in RA patient with low disease severity or remission who previously received a TNF inhibitor. In this trial, 30 patients who had been treated with the etanercept or infliximab were switched to GLM-SC for maintaining the disease activity at a low level. Patients were divided into the two groups through the discussion with each patient which considered the general conditions and convenience i.e the low disease activity (LDA) group and the LDAq8w group which included the patients with low disease activity or remission who permuted to the 50 mg GLM therapy at 4 and 8 week of interval, respectively. Effects of GLM-SC were evaluated at 12, 24 and 52 weeks after switching to the therapy. The mean disease activity score 28 erythrocyte sedimentation rate (DAS28-ESR) and disease activity score C-Reactive Protein (DAS-CRP) values in the LDA groups and LDAq8w groups were maintained from the baseline through the entire treatment period. Rates of DAS28-ESR remission were also maintained through week 52 from the baseline remission rates in the LDA and LDAq8w groups.

It was concluded that both GLM-SC treatment regimens were effective in maintaining the clinical response achieved with LDA, secondary to TNF inhibitors. At the end, no serious adverse events were noticed and the continuation rate at 52 weeks was 100% in both the groups. Therapeutic efficacy is adequately maintained in most patients switching from TNF inhibitor to GLM-SC. Patients who received the TNF inhibitor could seamlessly switched to the GLM-SC without any serious safety concerns.

Source:

Clinical Rheumatology

Link to the source:

http://link.springer.com/article/10.1007%2Fs10067-016-3502-8

Original title of article:

Maintenance of efficacy and safety with subcutaneous golimumab in rheumatoid arthritis patients with low disease activity who previously received TNF inhibitors

Authors:

Hiroki Wakabayashi, Hitoshi Inada, Yosuke Nishioka, Masahiro Hasegawa, Akihiro Sudo, Kusuki Nishioka

Clinical Rheumatology
Log in or register to post comments